<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01277107</url>
  </required_header>
  <id_info>
    <org_study_id>IN 09 006</org_study_id>
    <nct_id>NCT01277107</nct_id>
  </id_info>
  <brief_title>A Polysomnographic Study to Compare the Efficacy of Gastric Retentive Zaleplon Accordion Pill to Placebo in Subjects With Insomnia</brief_title>
  <official_title>Double Blind, Polysomnographic, Two-Way Crossover Study To Compere The Efficacy Of Gastric Retentive Zaleplon (Zaleplon AP) To Placebo In Subjects With Insomnia Characterized By Both Difficulty In Falling Asleep And Staying Asleep</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intec Pharma Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intec Pharma Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi center, double blind placebo controlled, two-way crossover study in patients
      with Insomnia suffering from difficulty in falling asleep and staying asleep. This study
      intends to assess the efficacy of Zaleplon AP in improving sleep parameters, comparing to
      placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the effect of dual release Zaleplon (Zaleplon AP) on Total Sleep Time (TST)</measure>
    <time_frame>Polysomnography tests for 2 consecutive nights at each treatment arm</time_frame>
    <description>The change from baseline on the mean of drug nights 1 and 2 relative to placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the efficacy of Zaleplon AP on Latency to Persistent Sleep (LPS)</measure>
    <time_frame>Polysomnography tests for 2 consecutive nights at each treatment arm</time_frame>
    <description>The change from baseline on the mean of drug nights 1 and 2 relative to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the efficacy of Zaleplon AP on Wake time After Sleep Onset (WASO)</measure>
    <time_frame>Polysomnography tests for 2 consecutive nights at each treatment arm</time_frame>
    <description>The change from baseline on the mean of drug nights 1 and 2 relative to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the presence of any residual effects using the digital symbol substitution test (DSST) and a memory test</measure>
    <time_frame>2 consecutive mornings at each treatment arm</time_frame>
    <description>The change from baseline on the mean of drug nights 1 and 2 relative to placebo.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">83</enrollment>
  <condition>Insomnia</condition>
  <arm_group>
    <arm_group_label>Zaleplon AP formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gastric Retentive Dual Release Zaleplon (Zaleplon AP)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Identical placebo capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zaleplon AP formulation</intervention_name>
    <description>Gastric retentive dual release Zaleplon</description>
    <arm_group_label>Zaleplon AP formulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo capsule</intervention_name>
    <description>Identical placebo capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects between the ages of 18 and 65 years of age

          -  Subjects that meet DSM IV diagnostic criteria for Primary Insomnia

          -  Subjects that report a time in bed ≥6.5 and ≤9 hours

          -  Subjects that report on a one week sleep diary (on at least 3 of 7 nights) TST ≤6.5
             hours

          -  Subjects that report on a one week sleep diary (on at least 3 of 7 nights)Wake time
             after sleep &gt;1.0 hour

          -  Subjects that report on a one week sleep diary (on at least 3 of 7 nights) ≥30 minutes
             time to sleep onset

          -  On two nights of PSG screening a mean WASO of ≥60 minutes with neither night less than
             45 minutes

          -  On two nights of PSG screening a mean LPS of ≥20 minutes with neither night less than
             15 minutes

          -  On two nights of PSG screening a TST of ≤6.5 hours on each of the two nights

          -  Body mass index of 18 - 34 inclusive

          -  Subjects that report a median habitual bedtime between 9:00pm (21:00 hours) and
             12:00am (00:00) on a one week sleep diary (based on 3 or more nights).

        Exclusion Criteria:

          -  Participation in another drug clinical trial within 1 month prior to first screening
             diary day (calculated from the previous study's last dosing date).

          -  On screening PSG night 1 an AHI &gt;10 (apnea hypopnea index)

          -  On screening PSG night 1 a PLMAI ≥10 (periodic limb movements with arousal)

          -  Subject has a circadian rhythm disorder including shift work or the need to travel ≥3
             time zones during the course of the study

          -  Subject has any other sleep disorder (e.g. Restless Legs Syndrome )

          -  Use of any drug known to effect sleep or wake functions within 5 half lives of the
             drug or two weeks, whichever comes first.

          -  Subject with a history (past year) of alcohol or substance abuse

          -  Subject that needs to smoke during the sleep period time

          -  Subject that reports habitual napping (more than 3 times per week)

          -  Subject has currently or a significant history of seizures, sleep apnea or restless
             leg syndrome or other sleep disorders which, in the opinion of the investigator
             responsible, contraindicates his/her participation

          -  Subjects with a recent history of clinically defined GERD, peptic ulcer or any
             gastrointestinal surgery other than appendectomy or herniotomy which, in the opinion
             of the investigator responsible, contraindicates his/her participation

          -  Subject with any gastrointestinal disorder likely to influence drug absorption, or
             with any history of inflammatory bowel disease, intestinal obstruction, irritable
             bowel syndrome, severe gastrointestinal narrowing, or frequent nausea or emesis,
             regardless of etiology which, in the opinion of the investigator responsible,
             contraindicates his/her participation

          -  Subjects suffering from any Axis 1 Psychiatric Disorder that in the opinion of the
             investigator responsible may interfere with full participation

          -  Subject has significant history of cardiac, pulmonary, hepatic or renal disease or
             other condition or any major complication/illness which, in the opinion of the
             investigator responsible, contraindicates his/her participation.

          -  The subject has any clinically important abnormal finding as determined by a medical
             history, physical examination, electrocardiogram, or clinical laboratory tests, as
             determined by the investigator

          -  Subject is taking CNS-active drugs (including herbal products with CNS effects), known
             to affect the sleep/wake cycle including but not limited to anxiolytic, hypnotics,
             antidepressants, sedating H1 antihistamines, systemic steroids, anticonvulsants,
             narcotic analgesics, respiratory stimulants respiratory decongestants, OTC and
             prescription diet aids, OTC and prescription stimulants, St. John's Wort, and
             melatonin.

          -  Females who are pregnant or nursing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pacific Sleep Medicine</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Broward Research Group</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRG of St. Petersburg</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vince and Associates Clinical Research</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam sleep center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2011</study_first_submitted>
  <study_first_submitted_qc>January 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2011</study_first_posted>
  <last_update_submitted>December 18, 2014</last_update_submitted>
  <last_update_submitted_qc>December 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PSG</keyword>
  <keyword>LPS</keyword>
  <keyword>TST</keyword>
  <keyword>WASO</keyword>
  <keyword>Subjects With Insomnia characterized by both Difficulty in Falling Asleep and Staying Asleep</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zaleplon</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

